Company / R&D Expense
Guardant Health, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$364.2M
FY2025
5-year range
$263.2M / $373.8M
FY2021-FY2025
Trend
+4.7%
vs FY2024
Sector context
#22 of 105
Health Care
What the data says
Guardant Health, Inc.'s r&d expense of $364M is higher than 79% of companies in the Health Care sector (FY2025). R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $364M.
Based on SEC 10-K filings.
$364M in FY2025 with a 5-year CAGR of +19.4%. Top quartile in the Health Care sector.
Remained stable around $364M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.9%
- 5-Year CAGR
- +19.4%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 105This company $364.2M Sector average $284.2M
▼
+28.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +19.4%, indicating consistent growth.
- In FY2025, r&d expense increased 4.7% year-over-year.
- Ranks #22 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $364.2M | +4.7% |
| FY2024 | $347.8M | -5.3% |
| FY2023 | $367.2M | -1.8% |
| FY2022 | $373.8M | +42.0% |
| FY2021 | $263.2M | +75.6% |
| FY2020 | $149.9M | +73.7% |
| FY2019 | $86.3M | +70.2% |
| FY2018 | $50.7M | +98.4% |
| FY2017 | $25.6M | +135.4% |
| FY2016 | $10.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026